A Study of Nivolumab, Ipilimumab, and Chemotherapy in Participants With Non-small Cell Lung Cancer
← catalyst calendarSponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
302actual
Sites
1
Country
Greece
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-10-19 | actual | When the study began enrolling |
| Primary completion | 2025-09-16 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-09-16 | actual | The whole study's end, after follow-up |
| First posted | 2022-10-31 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Carcinoma, Non-Small-Cell Lung
Primary outcomes
what the primary-completion date above is the date OFBaseline participant and disease characteristics of interest in the overall study population and the subpopulations per NSCLC histological subtype and PD-L1 expression level
measured Baseline
Number of NIVO/IPI/PBC doses administered in the overall study population and the subpopulations per NSCLC histological subtype and PD-L1 expression level
measured Up to 157 weeks
Time interval between infusions in the overall study population and the subpopulations per NSCLC histological subtype and PD-L1 expression level
measured Up to 157 weeks
Rate of dose modifications in the overall study population and the subpopulations per NSCLC histological subtype and PD-L1 expression level
measured Up to 157 weeks
Rate of permanent treatment discontinuation in the overall study population and the subpopulations per NSCLC histological subtype and PD-L1 expression level
measured Up to 157 weeks
Frequencies of reasons for dose modifications/discontinuations in the overall study population and the subpopulations per NSCLC histological subtype and PD-L1 expression level
measured Up to 157 weeks
Cumulative dose of NIVO and IPI administered in the overall study population and the subpopulations per NSCLC histological subtype and PD-L1 expression level
measured Up to 157 weeks
Relative dose intensity (RDI) in the overall study population and the subpopulations per NSCLC histological subtype and PD-L1 expression level
measured Up to 157 weeks
Proportion of participants receiving ≥90% RDI of NIVO and IPI in the overall study population and the subpopulations per NSCLC histological subtype and PD-L1 expression level
measured Up to 157 weeks
Time from NIVO/IPI/PBC initiation until discontinuation due to any reason in the overall study population and the subpopulations per NSCLC histological subtype and PD-L1 expression level
measured Up to 157 weeks
Proportions of participants surviving at the landmark timepoints of 12, 24, and 36 months after NIVO/IPI/PBC initiation in the overall study population and the subpopulations per NSCLC histological subtype and PD-L1 expression level
measured 12, 24, and 36 months
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed